Evidence map›Paper›PMID 39051310›Full record

ReviewClinics and practice2024

Revisiting Pulmonary Sclerosing Pneumocytoma.

Claudia Manini, Simone Vezzini, Antonella Conte, Giuseppe Sciacca, Alessandro Infantino, Poliana Santos-Pereira, José I López

Abstract readReview
In one paragraph

Review in Clinics and practice, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Claudia ManiniDepartment of Pathology, San Giovanni Bosco Hospital, ASL Città di Torino, 10154 Turin, Italy.
Simone VezziniPathology Unit, Department of Medical Sciences, University of Turin, 10126 Turin, Italy.
Antonella ContePathology Unit, Department of Medical Sciences, University of Turin, 10126 Turin, Italy.
Giuseppe SciaccaPathology Unit, Department of Medical Sciences, University of Turin, 10126 Turin, Italy.
Alessandro InfantinoFaculty of Medicine and Dentistry, University of Rome "La Sapienza", 00185 Rome, Italy.
Poliana Santos-PereiraDepartment of Pathology, San Giovanni Bosco Hospital, ASL Città di Torino, 10154 Turin, Italy.
José I LópezBiobizkaia Health Research Institute, 48903 Barakaldo, Spain.ORCID 0000-0003-0842-5348

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Pulmonary sclerosing pneumocytoma (PSP) is a quite rare tumor outside Eastern countries. This rarity, together with a wide histological appearance, makes its correct identification a diagnostic challenge for pathologists under the microscope. Historically, PSP was considered a vascular-derived neoplasm (sclerosing hemangioma), but its immunohistochemical profile clearly supports its epithelial origin. No specific molecular fingerprint has been detected so far. This short narrative revisits the clinical, histological, immunohistochemical, and molecular aspects of this tumor, paying special attention to some controversial points still not well clarified, i.e., clinical aggressiveness and metastatic spread, multifocality, the supposed development of sarcomatoid change in a subset of cases, and tumor associations with lung adenocarcinoma and/or well-differentiated neuroendocrine hyperplasia/tumors. The specific diagnostic difficulties on fine-needle aspiration cytology/biopsy and perioperative frozen sections are also highlighted. Finally, a teaching case of tumor concurrence of lung adenocarcinoma, neuroendocrine lesions, and PSP, paradigmatic of tumor association in this context, is also presented.

Indexed as

differential diagnosisimmunohistochemistrylung adenocarcinomapulmonary neuroendocrine hyperplasiapulmonary sclerosing pneumocytomawell-differentiated neuroendocrine tumor

Identifiers

PMID39051310
PMCPMC11270357

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.